Kalinox

Nitrous Oxide and Oxygen, the active ingredient in Kalinox, is an inhalational anesthetic presented as a medical gas for inhalation use. It provides analgesia and sedation for procedural pain management and serves as an adjunct to general anesthesia in surgical settings.

GNH USA supplies Kalinox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product is manufactured in the European Union and meets EU pharmacovigilance standards. It is distributed to a network of hospitals, transplant centres, oncology centres, pharmacies and clinics across multiple continents.

Kalinox, an inhalational anesthetic, is used for analgesia and sedation in several clinical settings.

Procedural analgesia: provides pain relief during minor surgical or diagnostic procedures. Sedation: facilitates patient comfort and cooperation during diagnostic imaging or dental work. Adjunct to general anesthesia: reduces anesthetic requirements and improves hemodynamic stability during major surgery.

Common Side Effects: - Nausea or vomiting - Dizziness or light‑headedness - Headache - Euphoria or mild hallucinations - Transient hypoxia if oxygen delivery is insufficient - Dry mouth or throat irritation

Serious or Rare Side Effects: - Severe respiratory depression - Loss of consciousness - Malignant hyperthermia (rare) - Cardiovascular collapse or severe hypotension - Pulmonary edema - Persistent neuropathy in patients with vitamin B12 deficiency

Kalinox should be administered only by trained personnel in a setting equipped for emergency airway management.

Assess respiratory function: ensure adequate oxygenation before administration. Monitor cardiovascular status: watch for hypotension or arrhythmias. Use in controlled environment: administer with resuscitation equipment readily available. Avoid in patients with severe COPD or obstructive airway disease. Contraindicated in known susceptibility to malignant hyperthermia. Store at ambient temperature: keep cylinder in original container, protect from heat and direct sunlight.

Kalinox may interact with other central nervous system depressants and certain anesthetic agents.

Major Interactions (Avoid): - Concurrent use with opioids or benzodiazepines may cause profound respiratory depression. - Combination with volatile anesthetics can increase risk of malignant hyperthermia. - Use in patients with vitamin B12 deficiency may exacerbate neuropathy.

Moderate Interactions (Monitor Closely): - Co‑administration with MAO inhibitors may affect hemodynamic stability. - Sedative antihistamines can increase overall sedation level. - Certain inhaled anesthetics may require dose adjustments when used together.